AzTrials
AzTrials

Urinary CalculiNCT05201599

Treatment of Upper Urinary Tract Stones With a Diameter≤2cm by Intelligent Pressure-controlled Flexible Ureteroscope

A study of Urinary Calculi, run by Guohua Zeng at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this trial is to compare the efficacy and safety of flexible ureteroscope with intelligent control of renal pelvic pressure (FURL-ICP) and traditional flexible ureteroscope(f-URL) in the treatment of upper urinary stones ≤ 2cm in diameter. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Urinary Calculi
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
449 participants
Where
1 siteChina
Study dates
11 Aug 2021to 31 Jul 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The diameter of single stone or cumulative maximum diameter for multiple stones is less than or equal to 2cm
  • American Society of Anesthesiology scores of 1to 2
  • All patients participate in this study voluntarily and signed informed consent

Who cannot join

  • Uncontrolled urinary tract infection
  • Patients with pyonephrosis are found during operation
  • The patients with abnormal anatomy (heterotopic kidney, horseshoe kidney, duplicate kidney), ureteral stricture, urethral stricture and urinary diversion
  • Severe hydronephrosis
  • Renal function was decompensated (serum creatinine > 178 μmol/L)
  • Severe systemic hemorrhagic disease
  • Patients who underwent bilateral surgery at the same time
  • Severe deformity of hip joint and difficult position

Trial locations and contacts

1 site in 1 country.

Zanlin Mai, Doctor contact

8613580359786

maizanlin1001@163.com

China1 site, 1 recruiting
  • The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People's Hospital)

    Ganzhou, Jiangxi, 341000

    Xiaolin Deng, Doctor, 18770738881, 279971368@qq.com

    Recruiting

Other trials in China

About this study

Official title: Treatment of Upper Urinary Tract Stones With a Diameter≤2cm by Flexible Ureteroscope With Intelligent Control of Renal Pelvic Pressure(FURL-ICP): a Multicenter, Parallel, Randomized Controlled Trial

The aim of this trial is to compare the efficacy and safety of flexible ureteroscope with intelligent control of renal pelvic pressure (FURL-ICP) and traditional flexible ureteroscope(f-URL) in the treatment of upper urinary stones ≤ 2cm in diameter. It is designed as a multicenter, parallel randomized controlled trial with two arms. At least 449 patients with upper urinary stones ≤ 2cm in diameter will be invited to participant in this study. Patients will be assigned to intervention group (FURL-ICP group) or control group (f-URL) by a simple random sampling technique with a rate of 1:1. The baseline of participants include demographic data, urine analysis, blood cell analysis, blood biochemical analysis, and urinary computer tomography (CT) with a slice thickness of 2mm. The primary outcomes are postoperative stone-free rate (SFR) of one month by CT scan and postoperative fever rate (body temperature > 38.5 ℃ within 3 days after operation). Secondary outcomes include operating time, degree of ureteral injury, SFR of one day.

Read the detailed description
  1. Background Urinary stone is a common disease with a prevalence rate of 5-15%. It has a recurrence rate of 50% for 5-10 years, and about 75% for 20 years. It is a heavy healthy burden to the population. Flexible ureteroscope lithotripsy(f-URL) is a first-line treatment for renal stone ≤ 2cm in diameter. It has the advantage of less trauma, low complications and fast recovery. It is also suitable for upper ureteral calculi, residual calculi after percutaneous nephrolithotomy (PCNL) It can also be combined with PCNL for the treatment of complex renal calculi. The postoperative stone free rate of f-URL varies drastically due to different sizes of residual stone. The Chinese consensus of flexible ureteroscopy recommended that stone ≤ 4mm in diameter should be considered as clinical insignificant residual stone. When residual stone was defined as ≤ 3mm, the stone free rate for one-month was 90% of renal stones ≤ 20 mm, and was 74.4% for stone of 10-25 mm. It would not cause significant symptoms when the residual stone ≤ 2 mm. Based on this definition, Fatih A's randomized trial showed that the stone free rate of f-URL for renal calculi ≤ 20 mm was 85.7%. It was only 30% for stone > 20 mm of single procedure,86.6% of secondary procedure, and 100% for tertiary procedure. When the residual stone was defined as ≤ 1 mm, the stone free rate of f-URL was 64.7% for a single procedure, 92% for secondary procedure, and the overall stone free rate was 85.1% and 100% for stone > 20 mm and ≤ 20 mm respectively by a retrospective study. When the stone free rate was defined as complete stone clearance, it was 71% after one month of single f-URL for renal stone >30mm . Postoperative infection is a common complication of f-URL. The key point to avoid postoperative infection includes to treat urinary infection, to keep a low flow perfusion and renal pelvic pressure (RPP) during operation, and to control the operation time. The renal pelvic pressure depends on the size of ureteral sheath and flexible ureteroscope, the flow of perfusion and outflow of traditional f-URL. It is difficult to realize real-time monitoring and regulation of renal pelvic pressure during the operation. To realize a high stone free rate and a low postoperative infection rate of f-URL, a new system named flexible ureteroscope with intelligent control of renal pelvic pressure (FURL-ICP) is designed and used. It has an irrigation and suctioning control platform, uses a ureteral access sheath with a pressure-sensitive tip, enables regulation of the infusion flow precisely, and controls the vacuum suctioning by computerized real-time recording and monitoring of RPP. A stable RPP is kept within a pre-set safe range by pressure feedback technology. The stone power could be sucked out during operation. Previous data showed that postoperative stone free rate was 90% for one day, and 95.6% for one month after operation respectively, and the overall complication rate was 14.4%. The aim of this study is to compare the efficacy and safety for FURL-ICP and f-URL in the treatment of upper urinary calculi with diameter ≤ 2cm.
  2. Objective To compare the efficacy and safety of FURL-ICP and traditional FURL for the treatment of ≤ 2cm upper urinary stones.
  3. Trial Design and Participants The trial is designed as a multicenter, parallel, randomized controlled trial with two arms. Patients will be recruited from 12 Chinese tertiary medical centers. Each participating center performed >50 f-URLs per month. Patients with upper urinary tract stones scheduled for f-URL will be invited in this study.
  4. Randomization and masking Central randomized allocation will be used without stratification. Participants will be assigned by a simple random sampling technique with a rate of 1:1. A randomization list is generated by a statistician and securely stored at a password-protected computer of the sponsor's center. Only one protocol-blinded coordinator will know the password and reveal the assignments in sequence to each center. The allocation is revealed before the surgery day. One-side superiority test is designed to compare the efficacy and safety of FURL-ICP and f-URL.
  5. Sample size Sample size is estimated by SFR of one month for f-URL. Complete stone free is defined as residual stone ≤ 2mm in diameter. The SFRs of FURL-ICP and traditional f-URL are presumed to be 90% (PT) and 75% (PC) respectively, based on previous data. 5% is considered as an inferior margin. The sample size is calculated with the formulas of a one-side superiority test comparing two proportions. The minimum sample size for each group was 224, and at least 449 cases are needed in the study. (https://www.cnstat.org/statx/compute.html).
  6. Intervention methods:

(1)Operation methods of intervention group(FURL-ICP): Each procedure is completed under general anesthesia in supine lithotomy position with 60-90° oblique on the affected side upward. A semi-rigid ureteroscopy is used to check the urinary tract system and to place a 0.032-inch guidewire. A pressure measuring ureteral access sheath (UAS) (11/13.8Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. A 7.5 Fr flexible ureteroscopy is used to check the delivery location of the UAS, mucosa of renal pelvis and ureter. After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscopy without basketing. A 4-6Fr ureteral stent is left for 2 weeks after the operation. Stone composition is analyzed. If the UAS is failed to be placed, ureteral stent will be placed for 2 weeks and a second stage FURL-ICP will be performed.

(2)Operation methods of control group(traditional f-URL): Each procedure is completed under general anesthesia in lithotomy position. A semi-rigid ureteroscopy is used to place a 0.032-inch guidewire. A pressure measuring ureteral access sheath (UAS) (11/13.8Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The irrigation and suctioning platform will be not used. A 7.5 Fr flexible ureteroscopy is used to break the stone with a holmium laser (fiber diameter 200 µm). A basket is used to remove the stone fragments. A 4-6Fr ureteral stent is left for 2 weeks after the operation. Stone composition is analyzed. If the UAS is failed to be placed, ureteral stent will be placed for 2 weeks and a second stage traditional f-URL will be performed.

Conditions
Urinary Calculi
Being tested
Flexible ureteroscope with intelligent control of renal pelvic pressure
Keywords
upper urinary stone, flexible ureteroscope, vacuum suction, stone free rate
Medical subject headings
Urinary Calculi

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Flexible ureteroscope with intelligent control of renal pelvic pressureDevice

    After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.

Study groups in NCT05201599
Study groupRoleWhat they receive
Flexible ureteroscope with intelligent control of renal pelvic pressure(FURL-ICP)ExperimentalPatients will be placed in supine lithotomy position with 60-90° oblique on the affected side upward. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The pressure sensory and suctioning channels are connected to the irrigation and suctioning platform.
Receives: Device: Flexible ureteroscope with intelligent control of renal pelvic pressure
Traditional flexible ureteroscope(f-URL)No interventionEach procedure is completed under general anesthesia in lithotomy position. A semi-rigid ureteroscopy is used to place a 0.032-inch guidewire. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The irrigation and suctioning platform will be not used. A 7.5 Fr flexible ureteroscopy is used to break the stone with a holmium laser (fiber diameter 200 µm). A basket is used to remove the stone fragments. A 4-6Fr ureteral stent is left for 2 weeks after the operation. Stone composition is analyzed. If the UAS is failed to be placed, ureteral stent will be placed for 2 weeks and a second stage traditional f-URL will be performed.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stone free rate for one month

    Stone free rate for one month after surgery by CT scan with a thickness of 2mm.

    Measured: One month after surgery

Secondary outcomes (4)
  1. Stone free rate for one day

    Stone free rate for one day after surgery by X-ray.

    Measured: One day after surgery

  2. Postoperative fever rate

    Postoperative fever rate (body temperature > 38.5°C within 3 days after operation

    Measured: Within 3 days after operation

  3. Operating time

    Operating time

    Measured: During the operation

  4. Degree of ureteral injury

    Degree of ureteral injury

    Measured: During the operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2022
  2. Study start11 Aug 2021
  3. Primary completion31 Jul 2022 (estimated)
  4. Study completion31 Jul 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients with upper urinary stones ≤ 2cm in diameter will be assigned to intervention group (FURL-ICP group) or control group (f-URL) by a simple random sampling technique with a rate of 1:1.
Masking
None (open label)
Enrolment
449 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05201599
Sponsor's protocol ID
MRER(49)2021
Status last verified
Jan 2022
First submitted
6 Oct 2021
Last updated
21 Jan 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: When the study is finished, we will shared data with other researchers.

Publications

  • Zeng G, Mai Z, Xia S, Wang Z, Zhang K, Wang L, Long Y, Ma J, Li Y, Wan SP, Wu W, Liu Y, Cui Z, Zhao Z, Qin J, Zeng T, Liu Y, Duan X, Mai X, Yang Z, Kong Z, Zhang T, Cai C, Shao Y, Yue Z, Li S, Ding J, Tang S, Ye Z. Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int. 2017 Jul;120(1):109-116. doi: 10.1111/bju.13828. Epub 2017 Mar 21.

    PubMed 28236332
  • Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006 Jan 28;367(9507):333-44. doi: 10.1016/S0140-6736(06)68071-9.

    PubMed 16443041
  • Farhan M, Nazim SM, Salam B, Ather MH. Prospective evaluation of outcome of percutaneous nephrolithotomy using the 'STONE' nephrolithometry score: A single-centre experience. Arab J Urol. 2015 Dec;13(4):264-9. doi: 10.1016/j.aju.2015.07.006. Epub 2015 Aug 29.

    PubMed 26609445
  • Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-5. doi: 10.1016/j.eururo.2012.03.052. Epub 2012 Mar 31.

    PubMed 22498635
  • Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius HG. Kidney stones. Nat Rev Dis Primers. 2016 Feb 25;2:16008. doi: 10.1038/nrdp.2016.8.

    PubMed 27188687
  • Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. 1999 Jul;162(1):27-30. doi: 10.1097/00005392-199907000-00007.

    PubMed 10379732
  • Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, Pace KT, Pais VM Jr, Pearle MS, Preminger GM, Razvi H, Shah O, Matlaga BR. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART I. J Urol. 2016 Oct;196(4):1153-60. doi: 10.1016/j.juro.2016.05.090. Epub 2016 May 27.

    PubMed 27238616
  • Guler Y, Erbin A, Ozmerdiven G, Yazici O. Comparison of Retrograde Intrarenal Surgery and Laparoscopic Surgery in the Treatment of Proximal Ureteral and Renal Pelvic Stones Greater than 15 mm. Folia Med (Plovdiv). 2020 Sep 30;62(3):490-496. doi: 10.3897/folmed.62.e48934.

    PubMed 33009767
  • Resorlu B, Unsal A, Ziypak T, Diri A, Atis G, Guven S, Sancaktutar AA, Tepeler A, Bozkurt OF, Oztuna D. Comparison of retrograde intrarenal surgery, shockwave lithotripsy, and percutaneous nephrolithotomy for treatment of medium-sized radiolucent renal stones. World J Urol. 2013 Dec;31(6):1581-6. doi: 10.1007/s00345-012-0991-1. Epub 2012 Nov 22.

    PubMed 23179732
  • Cvetkovic T, Kameric-Buljina M. [Comparative "in vitro" examination of permeability of rebasing made of phosphate cement and tubulitec aiming at chemical protection of dental pulp]. Stomatol Vjesn. 1986;15(1-2):23-7. No abstract available. Croatian.

    PubMed 3484138
  • Javanmard B, Kashi AH, Mazloomfard MM, Ansari Jafari A, Arefanian S. Retrograde Intrarenal Surgery Versus Shock Wave Lithotripsy for Renal Stones Smaller Than 2 cm: A Randomized Clinical Trial. Urol J. 2016 Oct 10;13(5):2823-2828.

    PubMed 27734422
  • Hussain M, Acher P, Penev B, Cynk M. Redefining the limits of flexible ureterorenoscopy. J Endourol. 2011 Jan;25(1):45-9. doi: 10.1089/end.2010.0236. Epub 2010 Nov 4.

    PubMed 21050026
  • Karakoyunlu N, Goktug G, Sener NC, Zengin K, Nalbant I, Ozturk U, Ozok U, Imamoglu A. A comparison of standard PCNL and staged retrograde FURS in pelvis stones over 2 cm in diameter: a prospective randomized study. Urolithiasis. 2015 Jun;43(3):283-7. doi: 10.1007/s00240-015-0768-2. Epub 2015 Apr 3.

    PubMed 25838180
  • Akbulut F, Kucuktopcu O, Kandemir E, Sonmezay E, Simsek A, Ozgor F, Binbay M, Muslumanoglu AY, Gurbuz G. Comparison of flexible ureterorenoscopy and mini-percutaneous nephrolithotomy in treatment of lower calyceal stones smaller than 2 cm. Ren Fail. 2016;38(1):163-7. doi: 10.3109/0886022X.2015.1128792. Epub 2016 Jan 4.

    PubMed 26727075
  • Yanaral F, Ozgor F, Kucuktopcu O, Sarilar O, Ayranci A, Savun M, Yuksel B, Binbay M. Comparison of Flexible Ureterorenoscopy and Mini Percutaneous Nephrolithotomy in the Management of Multiple Renal Calculi in 10-30 mm Size. Urol J. 2019 Aug 18;16(4):326-330. doi: 10.22037/uj.v0i0.3310.

    PubMed 30334245

Questions about this trial

What is this clinical trial studying?

A study of Urinary Calculi, run by Guohua Zeng at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Zanlin Mai, Doctor (8613580359786, maizanlin1001@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stone free rate for one month (time frame: One month after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05201599, which also lists 19 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in